Abstract
Tumor dissemination and invasive behavior are associated with a majority of cancer-related mortality cases. Loss of E-cadherin, which is caused by several tumor-promoting factors, is associated with metastasis and poor prognosis in many neoplasms. In this study, we aimed to identify small molecule compounds that restore the expression of E-cadherin, because these molecules are most likely to suppress tumor malignancy by restoring E-cadherin function and/or by inhibiting signals that suppress E-cadherin expression. Here, we developed a fluorescence screen system based on E-cadherin expression. A pilot drug library screen revealed that methotrexate (MTX) strongly induces E-cadherin expression in a colorectal cancer cell line, SW620. From the screen for 9600 compounds, we identified 9 hit compounds, which restored the expression of E-cadherin in SW620 and/or a melanoma cell line, SK-MEL-28. We confirmed that MTX and the other identified compounds transcriptionally promote E-cadherin expression. Among these, 2 compounds suppressed migration/invasion capacity in colorectal cancer cells and 3 in melanoma cells. A compound reduced SW620 migration and invasion with subtle effects on cell viability in SW620, SK-MEL-28, and a non-tumor cell line, HaCaT, with decrease in AKT and ERK1/2 protein levels. One of the other compounds reduced SK-MEL-28 cell migration and invasion and affected the viability only of SW620 and SK-MEL-28 cells but not HaCaT cells. These results suggest that these compounds would be attractive lead molecules as anti-metastasis agents.
| Original language | English |
|---|---|
| Pages (from-to) | 1419-1429 |
| Number of pages | 11 |
| Journal | Biochemical Pharmacology |
| Volume | 86 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
Keywords
- Colorectal cancer
- Compound
- E-cadherin
- Melanoma
- Methotrexate
- Small molecule screen
ASJC Scopus subject areas
- Pharmacology
- Biochemistry
Cite this
Identification of novel small compounds that restore E-cadherin expression and inhibit tumor cell motility and invasiveness. / Hirano, Tamaki; Satow, Reiko; Kato, Asami; Tamura, Mana; Murayama, Yumi; Saya, Hideyuki; Kojima, Hirotatsu; Nagano, Tetsuo; Okabe, Takayoshi; Fukami, Kiyoko.
In: Biochemical Pharmacology, Vol. 86, No. 10, 2013, p. 1419-1429.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Identification of novel small compounds that restore E-cadherin expression and inhibit tumor cell motility and invasiveness
AU - Hirano, Tamaki
AU - Satow, Reiko
AU - Kato, Asami
AU - Tamura, Mana
AU - Murayama, Yumi
AU - Saya, Hideyuki
AU - Kojima, Hirotatsu
AU - Nagano, Tetsuo
AU - Okabe, Takayoshi
AU - Fukami, Kiyoko
PY - 2013
Y1 - 2013
N2 - Tumor dissemination and invasive behavior are associated with a majority of cancer-related mortality cases. Loss of E-cadherin, which is caused by several tumor-promoting factors, is associated with metastasis and poor prognosis in many neoplasms. In this study, we aimed to identify small molecule compounds that restore the expression of E-cadherin, because these molecules are most likely to suppress tumor malignancy by restoring E-cadherin function and/or by inhibiting signals that suppress E-cadherin expression. Here, we developed a fluorescence screen system based on E-cadherin expression. A pilot drug library screen revealed that methotrexate (MTX) strongly induces E-cadherin expression in a colorectal cancer cell line, SW620. From the screen for 9600 compounds, we identified 9 hit compounds, which restored the expression of E-cadherin in SW620 and/or a melanoma cell line, SK-MEL-28. We confirmed that MTX and the other identified compounds transcriptionally promote E-cadherin expression. Among these, 2 compounds suppressed migration/invasion capacity in colorectal cancer cells and 3 in melanoma cells. A compound reduced SW620 migration and invasion with subtle effects on cell viability in SW620, SK-MEL-28, and a non-tumor cell line, HaCaT, with decrease in AKT and ERK1/2 protein levels. One of the other compounds reduced SK-MEL-28 cell migration and invasion and affected the viability only of SW620 and SK-MEL-28 cells but not HaCaT cells. These results suggest that these compounds would be attractive lead molecules as anti-metastasis agents.
AB - Tumor dissemination and invasive behavior are associated with a majority of cancer-related mortality cases. Loss of E-cadherin, which is caused by several tumor-promoting factors, is associated with metastasis and poor prognosis in many neoplasms. In this study, we aimed to identify small molecule compounds that restore the expression of E-cadherin, because these molecules are most likely to suppress tumor malignancy by restoring E-cadherin function and/or by inhibiting signals that suppress E-cadherin expression. Here, we developed a fluorescence screen system based on E-cadherin expression. A pilot drug library screen revealed that methotrexate (MTX) strongly induces E-cadherin expression in a colorectal cancer cell line, SW620. From the screen for 9600 compounds, we identified 9 hit compounds, which restored the expression of E-cadherin in SW620 and/or a melanoma cell line, SK-MEL-28. We confirmed that MTX and the other identified compounds transcriptionally promote E-cadherin expression. Among these, 2 compounds suppressed migration/invasion capacity in colorectal cancer cells and 3 in melanoma cells. A compound reduced SW620 migration and invasion with subtle effects on cell viability in SW620, SK-MEL-28, and a non-tumor cell line, HaCaT, with decrease in AKT and ERK1/2 protein levels. One of the other compounds reduced SK-MEL-28 cell migration and invasion and affected the viability only of SW620 and SK-MEL-28 cells but not HaCaT cells. These results suggest that these compounds would be attractive lead molecules as anti-metastasis agents.
KW - Colorectal cancer
KW - Compound
KW - E-cadherin
KW - Melanoma
KW - Methotrexate
KW - Small molecule screen
UR - http://www.scopus.com/inward/record.url?scp=84887064292&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887064292&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2013.09.001
DO - 10.1016/j.bcp.2013.09.001
M3 - Article
VL - 86
SP - 1419
EP - 1429
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
SN - 0006-2952
IS - 10
ER -